Alto Neuroscience Inc

Research Alto Neuroscience Inc (ANRO) on Bullrun: market cap USD 985.09M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerANRO
• ExchangeNYSE
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 985.09M
• Financial periodFY2025
• Net income-USD 63.24M
• Free cash flow-USD 51.79M

Valuation Snapshot

latest market cap is USD 985.09M.

About Alto Neuroscience Inc

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD);

Frequently asked questions

What is Alto Neuroscience Inc's market cap?

Alto Neuroscience Inc's market capitalization is USD 985.09M.

What does Alto Neuroscience Inc do?

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD).